BRADLEY PHARMACEUTICALS (BPRXA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BRADLEY PHARMACEUTICALS (BPRXA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Brad Glassma	3/24/1996 12:25:00 PM
	of 41

In the respiratory field, which comprises 60%-70% of the firm's revenue, DECONAMINE (a turbo sudafed)-- a prescription formula indicated for sinusitus and allerghic rhinitus leads the way. Some other products are PAMINE (anti-stomach spasm) and NITROGLYN (nitroglycerin)--internal medicine; CARMOL (urea cream) and TRANS-VER-SAL (wart remover) --DOAK DERMATOLOGY; GLUTOFAC (multivit and mineral) --nutritional; and LUBRIN (personal hygiene). The objective of this firm is to acquire products from large firms who are looking to divest small products not in their economies of scale or economies of scope. Then, retool these products and enhance thier profitability and market share. These cash flows are then aligned for larger acquisitions and substantial R&D. This is the same strategy that MERCK succeded with 50 years ago, AHP excelled with, and some recent success stories that utilized this strategy are DURA (DURA) Pharm and JONES MEDICAL (JMED)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next